| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA521: Guselkumab for treating moderate to severe plaque psoriasis |
|
Medicine details |
|
| Medicine name | guselkumab (Tremfya®) |
| Formulation | 100 mg solution for injection |
| Reference number | 3078 |
| Indication | Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Skin |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 05/10/2017 |
| NICE guidance | TA521: Guselkumab for treating moderate to severe plaque psoriasis |